ArticleFrontiers in physiology2026
Association between the apolipoprotein B/albumin ratio and the risk of kidney stones in adults.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kidney stones are widely considered a disease closely related to systemic metabolic disorders and systemic inflammation. The apolipoprotein B to albumin ratio (ApoB/Alb ratio) is a novel comprehensive biomarker that combines atherogenic lipid levels with systemic nutritional and inflammatory status. This study integrated data from two independent cohorts to explore the association between the serum ApoB/Alb ratio and the risk of kidney stones in adults. Methods: The Chinese single-center retrospective cohort included 741 subjects (223 kidney stone patients and 518 healthy controls) evaluated from March 2022 to September 2025. For external validation, 12,108 adult participants from the US National Health and Nutrition Examination Survey (NHANES) database (2007-2016) were included. Multivariate logistic regression analysis evaluated the independent association, while restricted cubic spline (RCS) smoothing curve fitting explored the dose-response relationship. Results: In the Chinese cohort, the serum ApoB/Alb ratio in the kidney stone group was significantly higher than in the control group (1.92 ± 0.52 vs. 1.84 ± 0.47, P = 0.048). After adjusting for comprehensive confounding factors, an elevated ApoB/Alb ratio was identified as a significant risk factor for kidney stones (OR = 3.26, 95% CI: 1.98-5.38). This significant positive association was highly consistent in the US NHANES validation cohort (OR = 1.30, 95% CI: 1.06-1.58). RCS analysis revealed a continuous positive linear dose-response relationship between the ApoB/Alb ratio and the prevalence of kidney stones in both cohorts. Furthermore, sensitivity and subgroup analyses demonstrated that this predictive value remains robust and is largely independent of traditional metabolic comorbidities such as hypertension and diabetes. Conclusion: As a comprehensive indicator of lipid metabolic disorders and inflammatory/nutritional imbalance, the ApoB/Alb ratio serves as a novel, highly sensitive, and reliable biomarker for predicting kidney stone risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.